Literature DB >> 17165100

Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients.

Y J La1, C L Wan, H Zhu, Y F Yang, Y S Chen, Y X Pan, G Y Feng, L He.   

Abstract

This study aims to identify the effects of antipsychotics on plasma proteins, and on the proteins associated with schizophrenia. We applied proteomics technology to screen protein aberrations in Sprague-Dawley rats treated with antipsychotics and schizophrenic patients undergoing medication. ApoA-I was found significantly increased in the chlorpromazine-treated rats and decreased in the patients with treatment-resistant schizophrenia, which suggest that decreased levels of apoA-I might be associated with the pathology of schizophrenia and that chlorpromazine increases apoA-I levels as part of its therapeutic action.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17165100     DOI: 10.1007/s00702-006-0607-2

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  31 in total

1.  The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description.

Authors:  R L Spitzer; J B Williams; M Gibbon; M B First
Journal:  Arch Gen Psychiatry       Date:  1992-08

2.  Differences in neuroanatomical sites of apoD elevation discriminate between schizophrenia and bipolar disorder.

Authors:  E A Thomas; B Dean; E Scarr; D Copolov; J G Sutcliffe
Journal:  Mol Psychiatry       Date:  2003-02       Impact factor: 15.992

3.  Association of APOE gene with schizophrenia in Chinese: a possible risk factor in times of malnutrition.

Authors:  Wanqing Liu; Gerome Breen; Jiangang Zhang; Sheng Li; Niufan Gu; Guoyin Feng; Shaochun Bai; Tao Shen; Albert Yu; Hong Xue; David St Clair; Lin He
Journal:  Schizophr Res       Date:  2003-08-01       Impact factor: 4.939

4.  Membrane-active agents. Effect of various anesthetics and chlorpromazine on arterial lipid metabolism.

Authors:  F P Bell; E V Hubert
Journal:  Atherosclerosis       Date:  1981-07       Impact factor: 5.162

5.  Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia.

Authors:  Brian Dean; Simon M Laws; Eugene Hone; Kevin Taddei; Elizabeth Scarr; Elizabeth A Thomas; Clive Harper; Catriona McClean; Colin Masters; Nicola Lautenschlager; Samuel E Gandy; Ralph N Martins
Journal:  Biol Psychiatry       Date:  2003-09-15       Impact factor: 13.382

6.  Antipsychotic drugs differentially modulate apolipoprotein D in rat brain.

Authors:  M M Khan; V V Parikh; S P Mahadik
Journal:  J Neurochem       Date:  2003-09       Impact factor: 5.372

7.  Structure and linkage of the D2 dopamine receptor and neural cell adhesion molecule genes on human chromosome 11q23.

Authors:  J H Eubanks; M Djabali; L Selleri; D K Grandy; O Civelli; D L McElligott; G A Evans
Journal:  Genomics       Date:  1992-12       Impact factor: 5.736

Review 8.  Chromosomal aberrations and schizophrenia. Autosomes.

Authors:  A S Bassett
Journal:  Br J Psychiatry       Date:  1992-09       Impact factor: 9.319

9.  Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome.

Authors:  Sahebarao P Mahadik; Mohammad M Khan; Denise R Evans; Vinay V Parikh
Journal:  Schizophr Res       Date:  2002-11-01       Impact factor: 4.939

10.  Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia.

Authors:  Cathryn M Lewis; Douglas F Levinson; Lesley H Wise; Lynn E DeLisi; Richard E Straub; Iiris Hovatta; Nigel M Williams; Sibylle G Schwab; Ann E Pulver; Stephen V Faraone; Linda M Brzustowicz; Charles A Kaufmann; David L Garver; Hugh M D Gurling; Eva Lindholm; Hilary Coon; Hans W Moises; William Byerley; Sarah H Shaw; Andrea Mesen; Robin Sherrington; F Anthony O'Neill; Dermot Walsh; Kenneth S Kendler; Jesper Ekelund; Tiina Paunio; Jouko Lönnqvist; Leena Peltonen; Michael C O'Donovan; Michael J Owen; Dieter B Wildenauer; Wolfgang Maier; Gerald Nestadt; Jean-Louis Blouin; Stylianos E Antonarakis; Bryan J Mowry; Jeremy M Silverman; Raymond R Crowe; C Robert Cloninger; Ming T Tsuang; Dolores Malaspina; Jill M Harkavy-Friedman; Dragan M Svrakic; Anne S Bassett; Jennifer Holcomb; Gursharan Kalsi; Andrew McQuillin; Jon Brynjolfson; Thordur Sigmundsson; Hannes Petursson; Elena Jazin; Tomas Zoëga; Tomas Helgason
Journal:  Am J Hum Genet       Date:  2003-06-11       Impact factor: 11.025

View more
  16 in total

Review 1.  Recent advances in neuroproteomics.

Authors:  Erika C Andrade; Dilja D Krueger; Angus C Nairn
Journal:  Curr Opin Mol Ther       Date:  2007-06

2.  Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia.

Authors:  Khaled Al Awam; Ida Sibylle Haußleiter; Ed Dudley; Rossen Donev; Martin Brüne; Georg Juckel; Johannes Thome
Journal:  J Neural Transm (Vienna)       Date:  2014-05-01       Impact factor: 3.575

3.  In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia.

Authors:  George Bartzokis; Po H Lu; Stephanie B Stewart; Bolanle Oluwadara; Andrew J Lucas; Joanna Pantages; Erika Pratt; Jonathan E Sherin; Lori L Altshuler; Jim Mintz; Michael J Gitlin; Kenneth L Subotnik; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2009-07-17       Impact factor: 4.939

4.  Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis.

Authors:  Daniel Martins-de-Souza; Wagner F Gattaz; Andrea Schmitt; Christiane Rewerts; Sérgio Marangoni; José C Novello; Giuseppina Maccarrone; Christoph W Turck; Emmanuel Dias-Neto
Journal:  J Neural Transm (Vienna)       Date:  2008-11-26       Impact factor: 3.575

5.  Schizophrenia-risk and urban birth are associated with proteomic changes in neonatal dried blood spots.

Authors:  Jason D Cooper; Sureyya Ozcan; Renee M Gardner; Nitin Rustogi; Susanne Wicks; Geertje F van Rees; F Markus Leweke; Christina Dalman; Håkan Karlsson; Sabine Bahn
Journal:  Transl Psychiatry       Date:  2017-12-18       Impact factor: 6.222

6.  Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia.

Authors:  Daniel Martins-de-Souza; Wagner F Gattaz; Andrea Schmitt; Christiane Rewerts; Giuseppina Maccarrone; Emmanuel Dias-Neto; Christoph W Turck
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-01-22       Impact factor: 5.270

7.  Dissecting the Syndrome of Schizophrenia: Progress toward Clinically Useful Biomarkers.

Authors:  Brian Dean
Journal:  Schizophr Res Treatment       Date:  2011-06-18

8.  APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia.

Authors:  Xueqin Song; Xue Li; Jinsong Gao; Jingping Zhao; Youhui Li; Xiaoduo Fan; Luxian Lv
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

9.  Myriocin-mediated up-regulation of hepatocyte apoA-I synthesis is associated with ERK inhibition.

Authors:  Elias N Glaros; Woojin S Kim; Brett Garner
Journal:  Clin Sci (Lond)       Date:  2010-03-30       Impact factor: 6.124

Review 10.  Proteomic profiling in schizophrenia: enabling stratification for more effective treatment.

Authors:  Paul C Guest; Daniel Martins-de-Souza; Emanuel Schwarz; Hassan Rahmoune; Murtada Alsaif; Jakub Tomasik; Christoph W Turck; Sabine Bahn
Journal:  Genome Med       Date:  2013-03-26       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.